Literature DB >> 24932626

Role of inflammation in non-allergic rhinitis.

E de Corso, M Battista, M Pandolfini, L Liberati, S Baroni, M Romanello, G C Passali, A R Fetoni, B Sergi, W Di Nardo, G Paludetti.   

Abstract

OBJECTIVE: To investigate the role of inflammation in non-allergic rhinitis (NAR) patients in a large series to establish the prevalence of different NAR-subtypes, clinical features and the role of nasal cytology in the diagnostic algorithm.
METHODOLOGY: Patients were selected out of 3650 individuals who spontaneously presented at our institution. We consecutively enrolled 519 NAR-patients in an analytical cross-sectional study between November 2007 and June 2013 (level of evidence: 3b). All patients underwent rhinological evaluation including symptoms questionnaire, endoscopy, CT scan, allergy tests and nasal cytology.
RESULTS: The inflammatory cell infiltrate affects the severity of symptoms differently, allowing for identification of different phenotypes of NAR. We distinguished two groups: “NAR without inflammation”(NAR-) and “NAR with inflammation”(NAR+), in addition to different NAR-subtypes with inflammation. A significant difference was observed in terms of clinical symptoms and association with comorbidities (previously diagnosed asthma and aspirin intolerance) between NAR–, NAR+ and between different NAR+ subtypes.
CONCLUSION: Our data suggest that NAR- and NAR with neutrophils behave similarly, showing lower symptom score values and a lower risk of association with comorbidities compared to NAR with eosinophils and mast cells (singularly or mixed). In our belief it is very important to establish the presence and type of inflammation in non-allergic rhinitis patients and nasal cytology is a very useful test in correct differential diagnosis.

Entities:  

Mesh:

Year:  2014        PMID: 24932626     DOI: 10.4193/Rhino13.102

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  7 in total

Review 1.  Neural Abnormalities in Nonallergic Rhinitis.

Authors:  Jonathan A Bernstein; Umesh Singh
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

Review 2.  Clinical Evidence of Type 2 Inflammation in Non-allergic Rhinitis with Eosinophilia Syndrome: a Systematic Review.

Authors:  Eugenio De Corso; Veronica Seccia; Giancarlo Ottaviano; Elena Cantone; Daniela Lucidi; Stefano Settimi; Tiziana Di Cesare; Jacopo Galli
Journal:  Curr Allergy Asthma Rep       Date:  2022-02-09       Impact factor: 4.806

3.  Radiofrequency volumetric inferior turbinate reduction: long-term clinical results.

Authors:  E De Corso; G Bastanza; V Di Donfrancesco; M L Guidi; G Morelli Sbarra; G C Passali; A Poscia; C de Waure; G Paludetti; J Galli
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-06       Impact factor: 2.124

Review 4.  Non-allergic rhinitis in children: Epidemiological aspects, pathological features, diagnostic methodology and clinical management.

Authors:  Dimitri Poddighe; Matteo Gelardi; Amelia Licari; Michele Miraglia Del Giudice; Gian Luigi Marseglia
Journal:  World J Methodol       Date:  2016-12-26

Review 5.  Capsaicin for Rhinitis.

Authors:  Wytske Fokkens; Peter Hellings; Christine Segboer
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

6.  Granulocyte-Macrophage Colony-Stimulating Factor Production and Tissue Eosinophilia in Chronic Rhinitis.

Authors:  Aleksandar Peric; Cveta Spadijer-Mirkovic; Svjetlana Matkovic-Jozin; Ljiljana Jovancevic; Danilo Vojvodic
Journal:  Int Arch Otorhinolaryngol       Date:  2016-02-26

Review 7.  Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology.

Authors:  Eugenio De Corso; Gianluca Bellocchi; Michele De Benedetto; Nicola Lombardo; Alberto Macchi; Luca Malvezzi; Gaetano Motta; Fabio Pagella; Claudio Vicini; Desiderio Passali
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-07-23       Impact factor: 2.618

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.